BlackRock’s Acer Therapeutics Inc ACER Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-76,772
Closed -$62.6K 5520
2023
Q3
$62.6K Hold
76,772
﹤0.01% 4962
2023
Q2
$70.9K Sell
76,772
-26,200
-25% -$23.2K ﹤0.01% 5005
2023
Q1
$78.1K Sell
102,972
-16,048
-13% -$31.7K ﹤0.01% 5027
2022
Q4
$299K Buy
119,020
+194
+0.2% +$333 ﹤0.01% 4744
2022
Q3
$166K Sell
118,826
-1,279
-1% -$1.85K ﹤0.01% 5026
2022
Q2
$151K Buy
120,105
+17,065
+17% +$35.7K ﹤0.01% 5112
2022
Q1
$300K Sell
103,040
-1,269
-1% -$3.06K ﹤0.01% 5017
2021
Q4
$237K Buy
104,309
+705
+0.7% +$1.64K ﹤0.01% 5071
2021
Q3
$265K Sell
103,604
-564
-0.5% -$1.43K ﹤0.01% 4917
2021
Q2
$299K Buy
104,168
+10,530
+11% +$30.3K ﹤0.01% 4813
2021
Q1
$291K Hold
93,638
﹤0.01% 4680
2020
Q4
$245K Hold
93,638
﹤0.01% 4447
2020
Q3
$270K Sell
93,638
-73,158
-44% -$236K ﹤0.01% 4356
2020
Q2
$573K Sell
166,796
-222,930
-57% -$629K ﹤0.01% 4180
2020
Q1
$775K Sell
389,726
-3,178
-0.8% -$11.6K ﹤0.01% 3948
2019
Q4
$1.58M Sell
392,904
-7,593
-2% -$25.8K ﹤0.01% 3856
2019
Q3
$1.28M Buy
400,497
+68,944
+21% +$202K ﹤0.01% 3895
2019
Q2
$1.29M Buy
331,553
+311,590
+1,561% +$5.94M ﹤0.01% 3933
2019
Q1
$485K Buy
19,963
+10,055
+101% +$237K ﹤0.01% 4105
2018
Q4
$199K Sell
9,908
-683
-6% -$15.7K ﹤0.01% 4236
2018
Q3
$327K Buy
10,591
+2,805
+36% +$75.1K ﹤0.01% 4220
2018
Q2
$168K Buy
7,786
+7,418
+2,016% +$141K ﹤0.01% 4355
2018
Q1
$7K Hold
368
﹤0.01% 4692
2017
Q4
$5K Hold
368
﹤0.01% 4731
2017
Q3
$7K Buy
368
+30
+9% +$291 ﹤0.01% 4718
2017
Q2
$2K Buy
338
+49
+17% +$325 ﹤0.01% 4923
2017
Q1
$2K Buy
+289
New +$2.84K ﹤0.01% 4909

Other funds holding ACER

BlackRock's ACER Position: Q4 2023 in Review

BlackRock sold out of Acer Therapeutics Inc (ACER) in Q4 2023, closing a stake of 76,772 shares — an estimated $62.6K sold.

BlackRock first reported a position in ACER in Q1 2017 and held it in 27 quarters. The position peaked at $1.58M in Q4 2019. 2 funds tracked by Wall St. Rank hold ACER as of Q4 2023.

  • BlackRock reported no remaining Acer Therapeutics Inc position as of Q4 2023 after selling out during the quarter.
  • BlackRock sold 76,772 Acer Therapeutics Inc shares in Q4 2023, an estimated $62.6K.
  • BlackRock first reported a position in Acer Therapeutics Inc in Q1 2017 and held it in 27 quarters.
  • BlackRock's Acer Therapeutics Inc position peaked at $1.58M in Q4 2019.
  • 2 funds tracked by Wall St. Rank held Acer Therapeutics Inc as of Q4 2023.

Based on BlackRock's 13F filing for Q4 2023, filed 13 Feb 2024.